Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.

Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM.

J Clin Psychopharmacol. 2009 Aug;29(4):362-7. doi: 10.1097/JCP.0b013e3181ac9b0b.

PMID:
19593176
2.

Aripiprazole for the maintenance treatment of bipolar I disorder: A review.

McIntyre RS.

Clin Ther. 2010;32 Suppl 1:S32-8. doi: 10.1016/j.clinthera.2010.01.022. Review.

PMID:
20152551
3.

Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Citrome L, Ketter TA, Cucchiaro J, Loebel A.

J Affect Disord. 2014 Feb;155:20-7. doi: 10.1016/j.jad.2013.10.040. Epub 2013 Oct 28. Review.

PMID:
24246116
4.

Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.

Pappadopulos E, Newcomer JW, Kolluri S.

J Clin Psychiatry. 2012 Jun;73(6):e742-8. doi: 10.4088/JCP.10r06802. Review.

PMID:
22795213
6.

A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.

Citrome L, Kalsekar I, Baker RA, Hebden T.

Curr Med Res Opin. 2014 Aug;30(8):1629-41. doi: 10.1185/03007995.2014.908280. Epub 2014 May 19. Review.

PMID:
24666104
7.

Current evidence for aripiprazole as augmentation therapy in major depressive disorder.

Khan A.

Expert Rev Neurother. 2008 Oct;8(10):1435-47. doi: 10.1586/14737175.8.10.1435. Review.

PMID:
18928339
8.

Aripiprazole: in major depressive disorder.

Weber J, Lyseng-Williamson KA, Scott LJ.

CNS Drugs. 2008;22(10):807-13. Review.

PMID:
18788833
9.

Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.

Pae CU, Forbes A, Patkar AA.

CNS Drugs. 2011 Feb;25(2):109-27. doi: 10.2165/11538980-000000000-00000. Review.

PMID:
21254788
10.

Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder.

Blier P, Blondeau C.

J Affect Disord. 2011 Jan;128 Suppl 1:S3-10. doi: 10.1016/S0165-0327(11)70003-9. Review.

PMID:
21220079
11.

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.

Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY.

Braz J Med Biol Res. 2014 Jul;47(7):605-16. Epub 2014 Jun 13. Review.

12.

Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.

Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S.

Gastroenterology. 2018 Apr;154(5):1309-1319.e7. doi: 10.1053/j.gastro.2017.12.024. Epub 2018 Jan 3. Review.

PMID:
29305933
13.

Treatment options for the patient who does not respond well to initial antidepressant therapy.

Preskorn SH.

J Psychiatr Pract. 2009 May;15(3):202-10. doi: 10.1097/01.pra.0000351880.30013.2a. Review.

PMID:
19461393
14.

ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).

Hopkins CR.

ACS Chem Neurosci. 2011 Oct 19;2(10):554. doi: 10.1021/cn200084v. Review.

15.

Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.

Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H.

Schizophr Bull. 2014 Nov;40(6):1385-403. doi: 10.1093/schbul/sbu030. Epub 2014 Mar 17. Review.

16.

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Maayan L, Vakhrusheva J, Correll CU.

Neuropsychopharmacology. 2010 Jun;35(7):1520-30. doi: 10.1038/npp.2010.21. Epub 2010 Mar 24. Review.

17.

Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.

McKeage K.

CNS Drugs. 2016 Feb;30(2):91-9. doi: 10.1007/s40263-016-0320-0. Review.

PMID:
26849053
18.

A review of pharmacotherapy of major depression in children and adolescents.

Ambrosini PJ.

Psychiatr Serv. 2000 May;51(5):627-33. Review.

PMID:
10783181
19.

The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.

Aftab A, Gao K.

Expert Opin Drug Discov. 2017 Oct;12(10):1067-1081. doi: 10.1080/17460441.2017.1354849. Epub 2017 Jul 18. Review.

PMID:
28718334
20.

A review of current evidence for vilazodone in major depressive disorder.

Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU.

Int J Psychiatry Clin Pract. 2013 Aug;17(3):160-9. doi: 10.3109/13651501.2013.794245. Epub 2013 May 29. Review.

PMID:
23578403

Supplemental Content

Support Center